Antiviral human monoclonal antibodies (mAbs) are promising drug candidates for preventing or treating severe viral diseases, but the long timelines—on the order of years—needed for antibody discovery, functional analysis, preclinical studies, and manufacturing limit their rapid deployment and use as immunotherapeutics.
Vanderbilt University Medical Center researchers Robert Carnahan and Pavlo Gilchuk are attempting to compress this timeline by integrating a series of advances in single-cell messenger RNA sequence analysis, bioinformatics, synthetic biology and high-throughput functional analysis. Their research provides a potential framework for expedited antibody discovery programs against viral pathogens of global concern.
During the webinar, viewers will:
Keynote Speaker Information: